Status:
COMPLETED
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
20-70 years
Phase:
PHASE1
Brief Summary
The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the bo...
Eligibility Criteria
Inclusion
- A body mass index (BMI=weight/height2) of 19 to 27 kg/m2
- Clinically normal physical findings, laboratory values and resting ECG as judged by the investigator
Exclusion
- ECG findings outside normal range
- Potassium outside normal reference values
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT00689039
Start Date
April 1 2007
End Date
July 1 2008
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Gothenburg, Sweden